VaccarinCAS# 53452-16-7 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 53452-16-7 | SDF | Download SDF |
| PubChem ID | 71307582 | Appearance | Yellow powder |
| Formula | C32H38O19 | M.Wt | 726.64 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Synonyms | Apigenin 4'-O-glucoside 6-C-(2-arabinosylglucoside) | ||
| Solubility | Soluble in methanol; sparingly soluble in water | ||
| Chemical Name | 6-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]-5,7-dihydroxy-2-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one | ||
| SMILES | C1C(C(C(C(O1)OC2C(C(C(OC2C3=C(C=C4C(=C3O)C(=O)C=C(O4)C5=CC=C(C=C5)OC6C(C(C(C(O6)CO)O)O)O)O)CO)O)O)O)O)O | ||
| Standard InChIKey | GYIKGLVKALOGDP-HLEFUGOVSA-N | ||
| Standard InChI | InChI=1S/C32H38O19/c33-7-17-23(40)26(43)30(51-31-27(44)21(38)14(37)9-46-31)29(49-17)20-13(36)6-16-19(24(20)41)12(35)5-15(48-16)10-1-3-11(4-2-10)47-32-28(45)25(42)22(39)18(8-34)50-32/h1-6,14,17-18,21-23,25-34,36-45H,7-9H2/t14-,17+,18+,21-,22+,23+,25-,26-,27+,28+,29-,30+,31-,32+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Vaccarin exhibits extensive biological activities including vascular endothelial cell protective effects, it can significantly promote neovascularization by enhancing protein expression of p-Akt , p‑Erk, and CD31, and selectively protect vascular endothelium from dysfunction induced by H2O2. |
| Targets | Akt | ERK | Caspase |
| In vitro | Vaccarin promotes endothelial cell proliferation in association with neovascularization in vitro and in vivo.[Pubmed: 25815517]Mol Med Rep. 2015 Jul;12(1):1131-6.Angiogenesis is a major pathological component of several diseases, including traumatic vascular disease and coronary heart disease. The purpose of the present study was to determine the effects of Vaccarin on endothelial cell migration and neovascularization, which are important and necessary components of wound healing. Vaccarin attenuates the human EA.hy926 endothelial cell oxidative stress injury through inhibition of Notch signaling.[Pubmed: 25352009]Int J Mol Med. 2015 Jan;35(1):135-42.Endothelial cell injury is an essential component of atherosclerosis and hypertension. Atherosclerosis and other macrovascular diseases are the most common complications of diabetes. Vaccarin is a major flavonoid glycoside in Vaccariae semen, and is expected to be useful in the treatment of vascular diseases. The aim of the present study was to evaluate the possible effects of Vaccarin in human umbilical vein endothelial cells (EA.hy926) induced by hydrogen peroxide (H2O2) and its underlying mechanism in the prevention and treatment of H2O2 injury. |
| Structure Identification | Zhongguo Zhong Yao Za Zhi. 2010 Aug;35(16):2072-4.Determination of vaccarin in Vaccariae Semen by HPLC.[Pubmed: 21046731]To establish a HPLC method for the determination of Vaccarin in Vaccariae Semen. |
Vaccarin Dilution Calculator
Vaccarin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.3762 mL | 6.881 mL | 13.762 mL | 27.5239 mL | 34.4049 mL |
| 5 mM | 0.2752 mL | 1.3762 mL | 2.7524 mL | 5.5048 mL | 6.881 mL |
| 10 mM | 0.1376 mL | 0.6881 mL | 1.3762 mL | 2.7524 mL | 3.4405 mL |
| 50 mM | 0.0275 mL | 0.1376 mL | 0.2752 mL | 0.5505 mL | 0.6881 mL |
| 100 mM | 0.0138 mL | 0.0688 mL | 0.1376 mL | 0.2752 mL | 0.344 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2-Aminonicotinic acid
Catalog No.:BCC8552
CAS No.:5345-47-1
- D-Leu-ol
Catalog No.:BCC2583
CAS No.:53448-09-2
- 2-Aminodiphenylamine
Catalog No.:BCC8548
CAS No.:534-85-0
- Erteberel (LY500307)
Catalog No.:BCC4491
CAS No.:533884-09-2
- Isovitexin 2'-O-arabinoside
Catalog No.:BCN7826
CAS No.:53382-71-1
- 1,3,5-Trihydroxy-4-prenylxanthone
Catalog No.:BCN5705
CAS No.:53377-61-0
- trans,trans-Bis(4-fluorobenzal)acetone
Catalog No.:BCC9180
CAS No.:53369-00-9
- Boc-N-Me-Leu-OH
Catalog No.:BCC2616
CAS No.:53363-89-6
- Z-Leu-OH.DCHA
Catalog No.:BCC2765
CAS No.:53363-87-4
- PP 3
Catalog No.:BCC7486
CAS No.:5334-30-5
- Isogosferol
Catalog No.:BCN5704
CAS No.:53319-52-1
- Benzyl carbazate
Catalog No.:BCC8872
CAS No.:5331-43-1
- 16-Kaurene-2,6,15-triol
Catalog No.:BCN5706
CAS No.:53452-32-7
- Creticoside C
Catalog No.:BCN5707
CAS No.:53452-34-9
- 4-Methoxycinnamyl alcohol
Catalog No.:BCN7515
CAS No.:53484-50-7
- Apohyoscine
Catalog No.:BCN1870
CAS No.:535-26-2
- Pipecolinic acid
Catalog No.:BCN8150
CAS No.:535-75-1
- Trigonelline
Catalog No.:BCN2371
CAS No.:535-83-1
- Marein
Catalog No.:BCN6477
CAS No.:535-96-6
- PIT 1
Catalog No.:BCC7873
CAS No.:53501-41-0
- 4,9,9'-Trihydroxy-3,3'-dimethoxy-8,4'-oxyneolignan
Catalog No.:BCN1425
CAS No.:53505-68-3
- 7-Amino-4-(Trifluoromethyl)Coumarin
Catalog No.:BCC9208
CAS No.:53518-15-3
- Durantoside II
Catalog No.:BCN4622
CAS No.:53526-66-2
- Durantoside I
Catalog No.:BCN4621
CAS No.:53526-67-3
[Determination of vaccarin in Vaccariae Semen by HPLC].[Pubmed:21046731]
Zhongguo Zhong Yao Za Zhi. 2010 Aug;35(16):2072-4.
To establish a HPLC method for the determination of Vaccarin in Vaccariae Semen. Analysis was carried out on an Alltima-C18 column (4.6 mm x 250 mm, 5 microm) eluted with methanol -0.3% phosphoric acid as mobile phase in gradient elution. The flow rate was 1.0 mL x min(-1) and detected wavelength was set at 280 nm. The peak areas and injection ammounts of Vaccarin showed a good linear relationship in the range of 0.102-1.539 microg, R2 = 0.9997. The average recovery was 100.4%, RSD was 0.81%. The results of the assay of 10 samples showed that the contents of Vaccarin varied in the range of 0.46%-0.57%. The method is simple, accurate, reproducible and specific. It can be used for the quality control of Vaccariae Semen.
Vaccarin promotes endothelial cell proliferation in association with neovascularization in vitro and in vivo.[Pubmed:25815517]
Mol Med Rep. 2015 Jul;12(1):1131-6.
Angiogenesis is a major pathological component of several diseases, including traumatic vascular disease and coronary heart disease. The purpose of the present study was to determine the effects of Vaccarin on endothelial cell migration and neovascularization, which are important and necessary components of wound healing. The present study investigated and confirmed neovascularization induced by Vaccarin in vitro and in vivo. In vitro, the effects of Vaccarin (1.08 and 2.15 microM) on proliferation, migration and tube formation of human microvascular endothelial cells (HMEC)-1 were evaluated via sulforhodamine B assay and migration and tube formation assay, respectively. Furthermore, a mouse Matrigel plus model was used to detect capillary-like tube structures in vivo. Immunohistochemistry was used to detect the protein expression of cluster of differentiation 31 (CD31), p-AKT and p-extracellular-signal-regulated kinases (Erk). Vaccarin significantly promoted HMEC-1 proliferation and migration and tube formation of HMEC-1 at a dose of 2.15 microM. In vivo, Vaccarin delivered by daily oral administration significantly improved epidermal growth factor-induced angiogenesis in an intradermal inoculation mouse model. The mouse Matrigel model study also revealed that Vaccarin significantly promoted neovascularization via detection of CD31 levels and enhanced protein expression of p-Akt and pErk. In addition, Vaccarin also promoted expression of CD31.
Vaccarin attenuates the human EA.hy926 endothelial cell oxidative stress injury through inhibition of Notch signaling.[Pubmed:25352009]
Int J Mol Med. 2015 Jan;35(1):135-42.
Endothelial cell injury is an essential component of atherosclerosis and hypertension. Atherosclerosis and other macrovascular diseases are the most common complications of diabetes. Vaccarin is a major flavonoid glycoside in Vaccariae semen, and is expected to be useful in the treatment of vascular diseases. The aim of the present study was to evaluate the possible effects of Vaccarin in human umbilical vein endothelial cells (EA.hy926) induced by hydrogen peroxide (H2O2) and its underlying mechanism in the prevention and treatment of H2O2 injury. In this study, the EA.hy926 cells were exposed to 250, 500 and 1000 microM H2O2 for 2 and 4 h in the absence or presence of Vaccarin, and the cell injury induced by H2O2 was examined via SRB. Cell migratory ability, lactate dehydrogenase (LDH) leakage, malondialdehyde (MDA) levels and decreasing superoxide dismutase (SOD) activity were evaluated by the wound healing assay and corresponding assay kits. Cell apoptosis was detected by flow cytometry with Annexin V-fluorescein isothiocyanate/propidium iodide Apoptosis Detection kit and Hoechst staining. Furthermore, western blot detected the protein expressions of Notch1, Hes1 and caspase-3. Following treatment with H2O2, it was found that H2O2 stimulated cell injury in a dose-dependent manner, including reducing cell viability and cell migratory ability, increasing LDH leakage and MDA levels, and decreasing SOD activity. H2O2 further accelerated cell apoptosis via activation of Notch1 and the downstream molecule Hes1. Preincubation with Vaccarin was found to protect EA.hy926 cells from H2O2-induced cell oxidative stress injury, which promoted cell viability and cell migratory ability, inhibited the level of LDH and MDA, but enhanced the activity of SOD. In particular, in addition to downregulation Notch signaling, Vaccarin treatments also downregulated caspase-3, a cell apoptotic pathway-related protein. These findings indicated that Vaccarin may be able to selectively protect vascular endothelium from dysfunction induced by H2O2.
